This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

LeadingBiotech: North CEO
October 1, 2020
Delivered Digitally | US Central Daylight Time

Henry Gosebruch
EVP, Chief Strategy Officer at Abbvie
Speaker

Profile

Henry Gosebruch is Executive Vice President and Chief Strategy Officer at AbbVie, a global biopharmaceutical company with a current market capitalization of approximately $170 billion and revenues of more than $50 billion. AbbVie employs approximately 46,000 people and markets medicines in more than 175 countries. As a member of AbbVie’s Executive Leadership Team, he is responsible for Corporate Strategy, R&D decision support/portfolio analytics, Business Development & Acquisitions, Search & Evaluation, Alliance Management and AbbVie Ventures. Henry and his team have completed over 75 business development/M&A transactions and venture capital investments since 2015. His organization consists of approximately 80 colleagues globally.


Prior to his AbbVie appointment in late 2015, Henry was Co-Head of J.P. Morgan’s North American M&A Group based in New York. He was a member of J.P. Morgan’s M&A group for more than 20 years where he worked on announced M&A transactions in excess of $375 billion in total value involving companies in more than 20 countries.


Henry is a German citizen and fluent in German. He graduated magna cum laude from the Wharton School at the University of Pennsylvania in 1995 with a BSE. Henry is a member of the board of directors at Aptinyx (APTX) and the advisory board of the Life Sciences & Management Program at the University of Pennsylvania. He is a licensed CPA and graduate of G100 Next Gen. Henry and his wife have three boys and live in Chicago.

Agenda Sessions

  • Keeping Your Exit Options Open

    12:20pm